Science News for ESC 2021

The American Heart Association's Science News from ESC 2021 coverage brings you results and insights into selected important scientific trials presented at ESC 2021, a virtual conference held August 27–30, 2021. Find at-a-glance data summaries, exclusive interviews, simultaneous publications, and more – all in one place.

Jump to one day's coverage: Friday  |  Saturday  |  Sunday  |  Monday

Quick Reference:
AHA Journals Simultaneous Publications

Friday's Selected Science

GUIDE-HF

Haemodynamic-guided management of heart failure – randomised arm primary outcomes
Joann Lindenfeld | Vanderbilt University, Nashville, TN

RESULTS: Hemodynamic-guided management across the spectrum of ejection fraction and symptom severity was safe but did not reduce a composite of mortality and HF events. However, the pre-COVID impact analysis indicated a benefit of hemodynamic-guided management on the primary outcome in the pre-COVID-19 period, primarily driven by a lower HF hospitalization rate compared to control group.

Simultaneous Publication

GUIDE HF Randomized Arm Primary Outcomes Results

Investigator Joann Lindenfeld recaps the results of GUIDE-HF randomized arm primary results and discusses the impact the COVID pandemic may have had on the outcome.

EMPEROR-Preserved

Effect of empagliflozin on cardiovascular death and heart failure hospitalisations in patients with heart failure with a preserved ejection fraction, with and without diabetes
Stefan Anker | Charite Campus Virchow Clinic, Berlin, Germany

RESULTS: Empagliflozin reduced the combined risk of cardiovascular death or heart failure hospitalization in patients with HFpEFby 21%, regardless of the presence or absence of diabetes. This benefit was consistent across pre-specified EF subgroups. Empagliflozin reduced total ( first and recurrent) hospitalizations for HF by 27%.

Simultaneous Publications


EMPEROR-Pooled

Effect of empagliflozin on serious adverse renal outcomes in chronic heart failure – a prospective alpha-protected, Individual patient-level pooled analysis
Milton Packer | Baylor University Medical Center, Dallas, TX

RESULTS: The effects of empagliflozin to reduce HF outcomes in EMPEROR-Preserved and EMPEROR-Reduced were highly concordant. Empaglifozin reduced HF hospitalizations by ≈ 30% across a broad range of EF from < 25% to < 65%, with attenuation of effect at higher ejection fractions. Empagliflozin reduced the risk of major renal outcomes in EMPORER-Reduced, but not in EMPEROR-Preserved.

Simultaneous Publication

EMPEROR-Preserved | EMPEROR-Pooled Trial Results

Investigators Stefan Anker and Milton Packer summarize the results of EMPEROR-Preserved and EMPEROR -Pooled trials, the first to show a positive result for a possible treatment for patients with heart failure with preserved ejection fraction with or without diabetes--the SGLT2 inhibitor empagliflozin.

Saturday's Selected Science

MASTER DAPT

Dual antiplatelet therapy after coronary stenting in high bleeding risk patients
Marco Valgimigli | Cardiocentro Ticino Foundation, Lugano, Switzerland

RESULTS: At least 2 additional months of therapy did not result in a significant increased occurrence of NACE or MACCE; Incidence of bleeding was significantly lower in patients receiving abbreviated therapy

Simultaneous Publication

MASTER DAPT

Investigator Marco Valgimigli recaps the results of MASTER DAPT.

FIGARO-DKD

Finerenone in patients with chronic kidney disease and type-2 diabetes
Bertram Pitt | University of Michigan, Ann Arbor, MI

RESULTS: Finerenone significantly reduced the risk of CV morbidity and mortality by 13%. Finerenone provides kidney and CV benefits across the spectrum of patients with CKD and T2D.


FIGARO-DKD Trial Results

Investigator Bertram Pitt recaps the results of FIGARO-DKD.

Sunday's Selected Science

ACST-2

Stenting vs. surgery for tight carotid stenosis
Alison Halliday | University of Oxford, Oxford, United Kingdom

RESULTS: Among asymptomatic patients receiving CAS or CEA, serious complications are uncommon, and both are associated with an approximately 1% risk of disabling stroke or death.


Commentary: ACST-2

Manesh Patel comments on the results of ACST-2.

LOOP Study

Screening for AF with an implantable loop recorder to prevent stroke
Jesper Hastrup Svendsen | Rigshospitalet, Copenhagen University Hospital, Heart Centre, Department of Cardiology, Copenhagen, Denmark

RESULTS: Continuous monitoring to detect atrial fibrillation via an implantable loop recorder and subsequent timely use of anticoagulants did not prevent stroke or systemic arterial embolism in high-risk individuals over 70 years old.


LOOP Study Results

Investigator Jesper Hastrup Svendsen summarizes the results of the LOOP Study.

Commentary: LOOP Study

Manesh Patel comments on the results of the LOOP Study.

Monday's Selected Science

STEP Study

Intensive vs. standard blood pressure control among older hypertensive patients
Jun Cai | Chinese Academy of Medical Sciences, Beijing, China

RESULTS: Intensive treatment for hypertension in older patients with a target systolic BP of 110 to less than 130 Hg. resulted in lower incidence of CV events than treatment with the target of systolic BP of 130 to 150 Hg.


Simultaneous Publication

STEP Study Results

Investigator Jun Cai recaps the results of the STEP Study.

American Heart Association Simultaneous Publications from ESC 2021

Compared Outcomes of ST-Elevation Myocardial Infarction Patients with Multivessel Disease Treated with Primary Percutaneous Coronary Intervention and Preserved Fractional Flow Reserve of Non-Culprit Lesions Treated Conservatively and of Those with Low Fractional Flow Reserve Managed Invasively: Insights from the FLOWER MI Trial
Pierre Denormandie, et al. | Circulation: Cardiovascular Interventions | Aug. 23, 2021

Effect of Colchicine on Myocardial Injury in Acute Myocardial Infarction
Kristina Lambrakis, et al. | Circulation | Aug. 23, 2021

Hemoglobin and Clinical Outcomes in the VerICiguaT Global Study in Patients With Heart Failure and Reduced Ejection Fraction (VICTORIA)
Justin A. Ezekowitz, et al. | Circulation | Aug. 25, 2021

Cardiovascular Benefit of Lowering LDL Cholesterol Below 40 mg/dl
Nicholas A. Marston, et al | Circulation | Aug. 27, 2021

Native Aortic Valve Disease Progression and Bioprosthetic Valve Degeneration in Patients with Transcatheter Aortic Valve Implantation
Jacek Kwiecinski, et al | Circulation | Aug. 29, 2021

Pulsed-Field Ablation in Ventricular Myocardium Using a Focal Catheter: The Impact of Application Repetition on Lesion Dimensions
Hagai D. Yavin, et al. | Circulation: Arrhythmia and Electrophysiology | Aug. 30, 2021

Influenza Vaccination After Myocardial Infarction: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial
Ole Frøbert, et al. | Circulation | Aug. 30, 2021

Cardiovascular Safety of Degarelix versus Leuprolide in Patients with Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial
Renato D. Lopes, et al. | Circulation | Aug. 30, 2021